CytoMed Therapeutics Limited
GDTCNASDAQHealthcare● Active
$1.07
$-0.09(-7.39%)
Market Cap$12601969
P/E Ratio—
52W High$3.68
52W Low$0.68
CytoMed Therapeutics Limited (GDTC) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · GDTC · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.32M | $0.07M | $0.51M | $0.37M | $0.00M |
| Cost of Revenue | $1.21M | $0.02M | $0.00M | $0.11M | $0.00M |
| Gross Profit | ($0.89M) | $0.05M | $0.51M | ($0.11M) | $0.11M |
| Gross Margin %(computed) | -277.74% | 75.37% | 99.27% | -29.83% | — |
| Operating Expenses | |||||
| R&D Expenses | $2.18M | $1.95M | $1.59M | $1.52M | $1.09M |
| G&A Expenses | $0.00M | $1.70M | $0.46M | $0.60M | $0.59M |
| Total Operating Expenses | $3.63M | $3.18M | $2.08M | $2.17M | $1.27M |
| Operating Income | ($4.52M) | ($3.13M) | ($1.58M) | ($2.28M) | ($1.16M) |
| Operating Margin %(computed) | — | — | -310.17% | -624.51% | — |
| Interest Income | $0.12M | $0.32M | $0.28M | $0.00M | $0.00M |
| Interest Expense | $0.02M | $0.02M | $0.05M | $0.12M | $0.12M |
| Income Before Tax | ($3.93M) | ($2.58M) | ($4.14M) | ($3.05M) | ($2.06M) |
| Income Tax Expense | $0.00M | $0.00M | $0.00M | $0.00M | $0.00M |
| Net Income | ($3.92M) | ($2.57M) | ($4.14M) | ($3.06M) | ($2.07M) |
| Net Margin %(computed) | — | — | -813.99% | -835.73% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.33 | $-0.22 | $-0.38 | $-0.40 | $-0.30 |
| Wtd Avg Shares | 11.65M | 11.54M | 10.63M | 7.92M | 6.93M |
| EBITDA | ($4.30M) | ($2.44M) | ($3.89M) | ($1.47M) | ($1.42M) |
| EBITDA Margin %(computed) | — | — | -763.58% | -403.07% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · SGD · M
Explore more CytoMed Therapeutics Limited data
About CytoMed Therapeutics Limited (GDTC) Income Statement
CytoMed Therapeutics Limited (GDTC) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, GDTC reported revenue of $0.00B, gross profit of ($0.00B) (gross margin -277.74%), and net income of ($0.00B) — a net profit margin of -1227.07%.
Frequently asked questions
GDTC · 4 questionsCytoMed Therapeutics Limited (GDTC) reported revenue of $0.00B for 2025, up 359.3% year-over-year.
GDTC revenueGDTC salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09